Regeneron promotes EYLEA, Libtayo, and Dupixent at JPMorgan event while touting a pipeline that targets major disease areas.

Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...

For patients hospitalized for COVID-19, administration of therapeutic-dose vs prophylactic-dose anticoagulation with heparins ...

Despite guidelines recommending other anticoagulants for people hospitalized with acute pulmonary embolism (PE), old habits ...

Whether early anticoagulation offers any additional benefits beyond that of dual antiplatelet therapy needs to be established by further trials.

Cadrenal Therapeutics (CVKD) recapped its 2024 milestones and highlighted a clear path forward to develop the investigational drug tecarfarin ...

In conclusion, monitoring intravenous UFH infusions with the anti-Xa HA compared to aPTT results in a more expeditious achievement of therapeutic anticoagulation, longer maintenance of therapeutic ...

For patients hospitalized for COVID-19, administration of therapeutic-dose versus prophylactic-dose anticoagulation with heparins is associated with lower 28-day mortality. HealthDay News — For ...

The researchers found that 28-day mortality was reduced with therapeutic-dose versus prophylactic-dose anticoagulation with heparins (odds ratio, 0.77; 95 percent confidence interval, 0.64 to 0.93 ...

The primary outcome in this study was the time to achieve therapeutic anticoagulation. For this analysis, data were truncated at the time therapeutic anticoagulation was achieved or the first 96 ...